Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24029349 | 0.85 | RXFP1 (0.61) | POLBMEN1KMT2A | |
| SCHEMBL24029355 | 0.71 | POLB (0.50) | POLBMEN1KMT2ASLC22A12ALDH1A1 | |
| SCHEMBL24209799 | 0.70 | RXFP1 (0.82) | POLBMEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL24209798 | 0.70 | SMN1; SMN2 (0.65) | POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL24019617 | 0.68 | NPSR1 (0.71) | POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL19079883 | 0.67 | USP2 (0.52) | POLBMEN1KMT2ASLC22A12ALDH1A1 | |
| SCHEMBL24209796 | 0.67 | MAPT (0.67) | MEN1KMT2AALDH1A1 | |
| SCHEMBL21589486 | 0.66 | PIK3C2A (0.77) | MEN1KMT2A | |
| SCHEMBL1704550 | 0.62 | CYP2D6 (0.73) | POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL5432468 | 0.62 | LMNA (0.47) | MEN1KMT2AALDH1A1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| WO-2021229035-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUNDACIÓN PROFESOR NOVOA SANTOS (ES) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | POLB 1121/4885MEN1 3372/4885KMT2A 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.